Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus

Bonaccorso, Stefania; Marino, Valentina; Biondi, Massimo; Grimaldi, F.; Ippoliti, Flora; Maes, Michaël

doi:10.1016/s0165-0327(02)00264-1

Cited by 246 publications

(156 citation statements)

References 21 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Likewise, past history of substance abuse (opioid or alcohol dependence) was not predictive of the development of depressive syndromes during treatment in our sample. Finally, as it has been noted in some 14,18,43 but not in all studies, 17 shows that most depression and anxiety syndromes induced by anti-viral therapy appeared during the first 4 weeks of treatment (59%) and more than 90% during the first 12 weeks. Nevertheless, it must be considered that we have assessed only the first 24 weeks of antiviral treatment and that it is possible that an indeterminate proportion of depression or anxiety syndromes may appear later.…”

Section: Discussionmentioning

confidence: 57%

De novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C

Martín‐Santos

Díez‐Quevedo

Castellví

et al. 2007

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackground Depression and anxiety have been associated with interferon treatment and low treatment adherence.Aim To study the incidence and associated risk factors of depressive and anxiety disorders during pegylated interferon plus ribavirin and treatment adherence in a prospective cohort of 176 patients with chronic hepatitis C patients.Methods Patients were interviewed at baseline using the Structured Clinical Interview for DSM‐IV Mental Disorders and the Patient Health Questionnaire and the Hospital Anxiety and Depression Scale were completed. Both questionnaires were completed also after 4, 12 and 24 weeks of treatment.Results De novo depressive and/or anxiety disorders were diagnosed in 53 (36%) patients, in whom antidepressants and/or anxiolytics were administered. Higher baseline depression‐subscale score (OR = 27.8, 95% CI = 2.82–333), primary education level (OR = 3.1, 95% CI = 1.40–7.03) and being an immigrant (OR = 3.2, 95% CI = 1.12–9.47) were predictors of psychiatric disorders during anti‐viral therapy. The percentage of patients with good adherence was lower in those with depression and/or anxiety (79% vs. 90%, P < 0.04). Only one patient (1%) discontinued treatment because of a major depressive episode. Depression and/or anxiety disorders had no effect on attainment of sustained virological response.Conclusion Early detection and treatment of depressive and anxiety disorders favours good adherence to anti‐viral treatment in hepatitis C.

show abstract

Section: Discussionmentioning

confidence: 57%

De novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C

Martín‐Santos

Díez‐Quevedo

Castellví

et al. 2007

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Conversely, in the context of clinical studies that follow patients using the cytokine interferon-a (IFN-a), some work has found that females who receive IFN-a are at greater risk of developing depression than males (Gohier et al, 2003;Koskinas et al, 2003). Still, others have reported no sex differences in either correlational relationships between inflammation and depression (Bremmer et al, 2008) or in IFN-a-induced depression (Bonaccorso et al, 2002). These mixed findings suggest that further studies are needed to better understand sex differences in this literature.…”

Section: Discussionmentioning

confidence: 99%

Sex Differences in Depressive and Socioemotional Responses to an Inflammatory Challenge: Implications for Sex Differences in Depression

Moieni

Irwin

Jevtić

et al. 2015

Neuropsychopharmacol

234

238

View full text Add to dashboard Cite

Substantial evidence demonstrates that inflammatory processes may underlie depression for a subset of patients, including work showing that healthy subjects exposed to an inflammatory challenge show increases in depressed mood and feelings of social disconnection. However, despite the fact that depression is two times as likely to occur in females than males, the vast majority of this work has been carried out in males. Thus, the objective of this study was to determine whether females (vs males) would show greater increases in proinflammatory cytokines, depressed mood, and social disconnection in response to an inflammatory challenge. One hundred and fifteen healthy participants (69 female) completed this double-blind, placebo-controlled, randomized clinical trial in which participants were randomly assigned to receive either a single infusion of low-dose endotoxin (derived from Escherichia coli; 0.8 ng/kg of body weight) or placebo (same volume of 0.9% saline). Interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), depressed mood, and feelings of social disconnection were assessed hourly. Results showed that endotoxin (vs placebo) led to increases in proinflammatory cytokines (TNF-a, IL-6), depressed mood, and feelings of social disconnection. Females exposed to endotoxin showed greater increases in depressed mood and feelings of social disconnection. Furthermore, increases in TNF-a and IL-6 were correlated with increases in social disconnection for females but not for males. These sex differences in the relationships between inflammatory and socioemotional responses to an inflammatory challenge may be particularly important for understanding why females are two times as likely as males to develop depressive disorders.

show abstract

“…In animal models, cytokine activation has produced depressive symptoms, a decreased hippocampal volume, and “sickness behavior” (Dunn, Swiergiel, & de Beaurepaire, 2005; Goshen et al., 2008; Lawson, McCusker, & Kelley, 2013). Immunotherapy with interleukin‐2 or interferon‐α is reportedly associated with cognitive impairment and a depressed mood as well as fatigue, sleep disturbances, irritability, and loss of appetite (Bonaccorso et al., 2001, 2002; Capuron, Ravaud, & Dantzer, 2001; Capuron et al., 2001; Dieperink, Willenbring, & Ho, 2000). Vaccines, which act as cytokine inducers, also cause a depressed mood in healthy individuals (Harrison et al., 2009).…”

Section: Introductionmentioning

confidence: 99%

Low tumor necrosis factor‐α levels predict symptom reduction during electroconvulsive therapy in major depressive disorder

et al. 2018

View full text Add to dashboard Cite

ObjectiveChanges in the tumor necrosis factor‐α (TNFα) have been associated with major depressive disorder (MDD). Findings concerning the effects of electroconvulsive therapy (ECT) on the TNFα level have been contradictory. The aim was to examine the immediate and long‐term changes in the TNFα level and their associations with symptom reduction in patients with MDD during ECT.MethodThe study included 30 patients with MDD. Their TNFα levels were measured at baseline and 2 and 4 hr after the first, fifth and last ECT session. Depressive symptoms were assessed with the Montgomery‐Asberg Depression Rating Scale (MADRS).ResultsThe TNFα level decreased from baseline to the 2‐ and 4‐hr measurements. There was a correlation between the first ECT session TNFα levels and the relative symptom reduction according to the MADRS score after the ECT series. Both the first (baseline) ECT and 4‐hr TNFα levels were lower in responders than in nonresponders.Conclusion ECT consistently induced a decrease in the TNFα level after each studied session. A low TNFα level at the first ECT appeared to predict a symptom reduction. These findings suggest that TNFα might have a role in the pathogenesis in MDD and in the mechanism of action of ECT.

show abstract

Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus

Cited by 246 publications

References 21 publications

De novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C

De novo depression and anxiety disorders and influence on adherence during peginterferon‐alpha‐2a and ribavirin treatment in patients with hepatitis C

Sex Differences in Depressive and Socioemotional Responses to an Inflammatory Challenge: Implications for Sex Differences in Depression

Low tumor necrosis factor‐α levels predict symptom reduction during electroconvulsive therapy in major depressive disorder

Contact Info

Product

Resources

About